Obesity and asthma are 2 of the most highly prevalent and challenging public health conditions in children worldwide. 1 The World Health Organization (WHO) reported that more than 42 million children less than 5 years of age were overweight or obese globally in 2010, with projections reaching 70 million by 2025. 2 During the past 20 years, the increase in asthma prevalence paralleled that of obesity, suggesting a possible link between the 2 conditions. 3, 4 It is estimated that approximately 300 million persons have asthma, 5, 6 with asthma exacerbations being a major cause of childhood hospitalization in North America. [7] [8] [9] Together, asthma and obesity lead to substantial morbidity, impaired quality of life, and health care burden in developed countries. 7 Obese patients appear to present with a more severe and difficult-tomanage clinical phenotype of asthma, 10 which might be less responsive to conventional therapies. 11 As a result, some experts have questioned the appropriateness of current management guidelines for obese patients with asthma. 12 Inhaled corticosteroids (ICSs) are the cornerstone of symptom management in childhood asthma. [13] [14] [15] [16] In children whose symptoms are insufficiently controlled by low-dose ICSs, management guidelines recommend increasing to a medium-or high-dose ICS monotherapy or adding adjunct therapy, such as long-acting b-agonists (LABAs) or leukotriene receptor antagonists (LTRAs), to a low-or medium-dose ICS (step 3). 15, 17 Step 3 therapy can also be initiated without a prior trial of low-dose ICSs in children with troublesome daily symptoms or at high risk of poor asthma outcomes, such as severe exacerbations. 13 However, contrary to the highly prevalent ICS-responsive eosinophilic phenotype, accumulating evidence supports a noneosinophilic inflammatory mechanism for the obese-asthma phenotype, raising the possibility that ICSs might be less effective in this population. [18] [19] [20] [21] A variety of mechanisms underlying the obese-asthma phenotype have been postulated, from weight-induced stress on lung mechanics to an imbalance in proinflammatory markers and genetic polymorphisms negatively influencing airway tone. 22 Asthmatic children with excess weight have been shown to experience a higher risk of rescue b 2 -agonist use, exacerbations, [23] [24] [25] school absenteeism, 26 blunted response to ICSs, 27, 28 lower pulmonary function, and higher symptom expression when compared with their normal-weight counterparts. 26, [29] [30] [31] However, other studies do not support these claims. [31] [32] [33] [34] [35] [36] [37] Such inconsistencies might be due to (1) unconfirmed asthma diagnosis or lack of clinical severity indicators, (2) reliance on self-reported asthma control, (3) differential follow-up times or censoring, (4) study populations that assume patients initiating maintenance therapies (incident users) are similar to those using them for some time (prevalent users), and (5) the inability to account for differences in treatment response because of variable adherence during follow-up. The goal of maintenance therapy is to improve symptom-free periods, reducing the risk of exacerbations and other adverse outcomes for all patients. 13 Consequently, the effect of weight status on treatment response remains to be further elucidated in children with asthma, particularly those at higher risk of exacerbations and poor control.
With evidence suggesting a noneosinophilic inflammatory mechanism as a characteristic of the obese-asthma phenotype, we hypothesized that obese children would be more likely to respond to ICS/LABA or ICS/LTRA treatment, with combination therapies conferring an additional benefit than ICSs alone, and this differential response might lead to an increased risk of exacerbation among children with obesity. Therefore the primary objectives of this study were to assess whether, among children with asthma, obesity (1) is associated with the time to first exacerbation in incident users of step 3 maintenance therapies, namely medium/high-dose ICS monotherapy and low/medium-dose ICS in combination with LABA or LTRA, and (2) modifies the relative effectiveness of step 3 maintenance therapies with regard to the duration of the exacerbation-free period after treatment initiation.
METHODS

Research design
A retrospective cohort study was conducted by using a large clinical database linked to provincial administrative medical health care and drug databases. The Pediatric Asthma Database comprised all children who consulted or were followed at the Asthma Center of the Montreal Children's Hospital, a pediatric tertiary care university hospital, between 2000 and 2007. A total of 4,621 unique patients contributed 15,147 clinic visits. The study was approved by the institutional Research Ethics Boards of the CHU Sainte-Justine and MCH, the Commission d'acc es a l'information, and the R egie de l'assurance maladie du Qu ebec.
Data sources
The Pediatric Asthma Database included patients' demographics, anthropometrics, specialist-confirmed asthma diagnosis, asthma severity and control indicators, environmental triggers, spirometric test results
Abbreviations used
BMI: Body mass index HFA-BDP eq : Hydrofluroalkane-propelled beclomethasone dipropionate or equivalent HR: Hazard ratio ICD-9/ICD-10: International Classification of Diseases 9th and 10th revisions of diagnostic codes ICS: Inhaled corticosteroid IPCW: Inverse probability of censoring weights IPTW: Inverse probability of treatment weights LABA: Long-acting b-agonist LTRA: Leukotriene receptor antagonist MSM: Marginal structural model WHO: World Health Organization (if cooperative), and physician prescription records of all asthma maintenance and/or rescue treatments. This database was linked to the hospital admission (MED-ECHO), R egie de l'assurance maladie du Qu ebec medical service, and prescription claims databases. The medical service database includes procedure codes, type and location of service delivery (eg, emergency, inpatient, and ambulatory services), and International Classification of Diseases, 9th and 10th revision (ICD-9 and ICD-10, respectively), diagnostic codes for all medical services billed by physicians. 38 The MED-ECHO database contains admission and discharge information for all acute care hospitalizations. 39 In Quebec, all children are offered free medical services and admissions. The prescription claims database includes information on drugs dispensed for patients enrolled in the Quebec Public Drug Insurance Plan, covering approximately 42% of Quebec residents.
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Study population
Patients were included if they were aged 2 to 18 years, presented at the asthma center between April 2000 and September 2007, had specialist-diagnosed asthma, and initiated one of the following step 3 maintenance therapies, as documented in the medical chart at the visit date: (1) medium/high-dose ICS monotherapy (hereafter referred to as ICS monotherapy) or (2) low/medium-dose ICSs with a LABA or LTRA (termed combination therapy). We did not include initiators of high-dose ICSs with LABAs or LTRAs in the combination therapy group. A 3-month washout period was instated to ascertain incident use (ie, patients receiving ICS monotherapy and combination therapy must have had no recent drug claims of medium/high-dose ICSs and LABAs or LTRAs, respectively). Patients were excluded if they (1) had bronchopulmonary dysplasia or cystic fibrosis, (2) were prescribed oral corticosteroids as a maintenance therapy, or (3) were not covered by the public drug insurance plan at least 3 months before and after the visit date. The cohort entry (index) date was defined as the date at which patients met all inclusion criteria. The cohort end date was defined as the outcome date, end date of insurance coverage, 1-year follow-up, or December 31, 2007, whichever occurred first.
Outcome
An asthma exacerbation was defined as a composite end point, including (1) a short course of oral corticosteroids, (2) an acute care visit, or (3) hospital admission related to an asthma exacerbation (ICD-9 code 493.X and ICD-10 code J45.X), whichever occurred first. A lag period of 3 days was instated after cohort entry to exclude pre-existing exacerbations.
Time-varying exposures
Body mass index percentile and obesity. Age-and sex-specific z score-based body mass index (BMI) percentiles were calculated by using WHO growth standard reference values, with height and weight measurements recorded in medical charts by trained health care professionals. 42 The WHO international growth charts for preschoolers and children aged 5 to 19 years have been recommended as the gold standard for growth monitoring by the Dietitians of Canada, the Canadian Pediatric Society, the College of Family Physicians of Canada, and the Community Health Nurses of Canada. 43 Because of growth spurts and weight fluctuations in children, BMI percentile values were updated during follow-up at each subsequent visit to the asthma center. Despite the recommended and more conservative obesity cutoff of a BMI of greater than the 99.9th percentile for preschoolers, obesity was defined as a BMI of greater than the 97th percentile for all ages, which is in accordance with Canadian guidelines for children aged 5 years and older, to improve uniformity, clarity, and ease of interpretation. 43, 44 Treatment. A time-varying treatment exposure definition was used to classify step 3 maintenance therapy groups during follow-up. Children dispensed medium-and high-dose ICSs (ie, 201-400 and >400 mg/d [251-500 and >500 mg/d if > _12 years old], respectively, of hydrofluoroalkane-propelled beclomethasone dipropionate or equivalent [HFA-BDP eq ] measured ex-valve 15 without add-on therapies) were classified as exposed to ICS monotherapy for the duration of the claim. Patients dispensed a low-dose ICS (ie, < _200 mg/d or < _250 mg/day if > _12 years old of HFA-BDP eq measured ex-valve) or a medium-dose ICS with a LABA (fluticasone/salmeterol, budesonide/formoterol, beclomethasone/formeterol, and mometasone/formoterol) or LTRA (montelukast or zafirlukast) were classified as exposed to combination therapy for the duration of the claim. In the event of discordance between the medical chart and prescription claims database on ICS daily dose, a correction factor was applied to the duration of the claim to reflect prescription data recorded in the medical chart (gold standard) at the index date. Intervals of nonadherence (ie the absence of a drug claim for any of the step 3 maintenance therapies) were classified as ''no-use'' periods. No-use periods began the day after the expected completion date of the most recent prescription claim, assuming adherence, and ended the day before the dispensation date of a new claim for step 3 maintenance therapies.
Time-fixed and time-varying covariates
Age, sex, ethnicity, average neighborhood income based on 6-digit postal code, environmental triggers, asthma phenotype, asthma-related comorbidities, and number of exacerbations in the preceding year were documented at the index visit and were considered time-fixed covariates. The physicians' global assessment of asthma severity and prebronchodilator percent predicted FEV 1 values were updated at every subsequent asthma center visit and considered time-dependent covariates. We controlled for season to account for environmental triggers associated with respiratory tract infection (October 1 to March 31) and allergies (April 1 to September 31).
Statistical analysis
Multiple imputations (n 5 5) were used to address missing data for BMI percentile (3.4%), ethnicity (8.2%), percent predicted FEV 1 (23.5%), exposure to smoke (25.6%), and income (21.3%) at cohort entry. The Andersen-Gill extension of the Cox model was used to generate conditional estimates for maintenance therapy and obesity with respect to the hazard of first exacerbation while adjusting for time-varying and time-fixed covariates. 45 Two Cox marginal structural models (MSMs) for obesity and treatment were also fit. 46, 47 The MSMs generate marginal hazard ratios (HRs) had all patients been, contrary to fact, consistently exposed or unexposed to obesity or to the treatment groups of interest under full compliance throughout follow-up.
To correct for the possible survival bias induced by the HR, 48 we used the inverse probability of remaining event-free for the estimation of censoring weights to simulate the survival experiences of patients susceptible to early exacerbations had they remained under observation (see the Methods section and Fig E1 in this article's Online Repository at www.jacionline.org for a detailed explanation of the differences between conditional and marginal models). This weighting approach has similar conceptual underpinnings to the inverse probability of censoring weights (IPCW) correction for artificial censoring. 49 The resulting conditional and marginal models were then used, rather than empiric data, to estimate exacerbation-free survival curves for obesity and treatment status, allowing for potential time-varying effects. 48 The proportional hazards assumption was evaluated by verifying the smoothed approximation of the scaled Schoenfeld residuals plot with linear or log-transformed time. Based on the graphic assessment of the form of this relationship, a product term with the appropriate transformation of time (eg, log, linear, or squared) was included for covariates violating the proportional hazards assumption.
To obtain marginal estimates for the joint effect of treatment and obesity on the hazard of exacerbation, stabilized weights were computed and used subsequently to fit the joint MSM. 50 When evaluating treatment effect modification by obesity status, we computed the relative excess risk due to interaction 51 for the marginal model and likelihood ratio test, which assesses improved fit with the obesity and treatment interaction term for the marginal and conditional models, respectively. The robust sandwich estimator was used to account for the weighting of subjects in our sample.
The following sensitivity analyses were performed post hoc to assess the robustness of our findings: (1) acute care visits were excluded from the definition of exacerbation, (2) only complete cases were included, and (3) different BMI cutoffs for obesity (>99.9th and >95.5th percentiles for children aged 2-4 and 5-19 years, respectively) were used. Data cleaning and the calculation of stabilized weights were performed with SAS software (version 9.4; SAS Institute, Cary, NC), survival curves were illustrated with Stata Statistical Software (Release 13; StataCorp, College Station, Tex), and the analysis of all models was performed with R Studio software, version 1.0.44.
RESULTS
Of the 4621 patients enrolled in the Pediatric Asthma Database, 328 children were incident users of ICS monotherapy (n 5 231) or combination therapy (n 5 97, Fig 1) . Children initiating combination therapy were generally older, had more severe symptoms, had persistent asthma, more commonly received previous maintenance therapy, had a higher number of acute care visits in the previous year, and reported symptoms triggered frequently by exercise and allergies than those initiating ICS monotherapy at cohort entry (Table I) .
There were 225 exacerbations during 8469 person-weeks of follow-up (Table II) . Obese children with asthma had a significantly shorter exacerbation-free period than nonobese children (Fig 2) . The average HR for obesity on time to first exacerbation was 1.22 (95% CI, 0.91-1.64) and 1.67 (95% CI, 1.41-1.98) in the conditional and marginal models, respectively.
Children exposed to combination therapy had a longer exacerbation-free period than those exposed to ICS monotherapy maintenance regimens, although this difference was not statistically significant (Fig 3) . The average conditional HRs for ICS monotherapy and combination therapy were 0.81 (95% CI, 0.59-1.13) and 0.60 (95% CI, 0.33-1.07), respectively (Fig 4) . The marginal treatment model produced similar results. The average conditional and marginal HRs by obesity status and treatment group using a common reference (children unexposed to both obesity and maintenance therapies) were also estimated (Table III) . When compared with nonobese children not adhering to their prescribed therapies (ie, the jointly unexposed), the marginal average HR for (1) nonadherent obese children was 1.54 (95% CI, 0.97-2.45), (2) nonobese children receiving ICS monotherapy was 0.58 (95% CI, 0.37-0.91), (3) obese children receiving ICS monotherapy was 0.85 (95% CI, 0.47-1.52), (4) nonobese children receiving ICS combination ICU, Intensive care unit; NA, not available. *Low, medium, and high daily dose levels were defined as less than 200, 201 to 400, and greater than 400 mg, as well as 250 mg or less, 251 to 500 mg, and greater than 500 mg of HFA-BDP eq dose equivalents measured ex-valve for children aged less than 12 years and 12 years and older, respectively. Categories are not mutually exclusive. àAtopic conditions comprise eczema, allergic rhinitis, conjunctivitis, and food allergies.
§Chronic upper or lower respiratory tract comorbidities include recurrent otitis, sinusitis, pneumonia, gastroesophageal reflux disease, obstructive sleep apnea, bronchopulmonary aspergillosis, and vocal cord dysfunction or dysphagia. Table E1 in this article's Online Repository at www.jacionline. org. Compared with the lowest-risk reference group (ie, normal-weight children using combination therapy), the relative excess risk for children jointly exposed to obesity and ICS monotherapy was 0.49 (95% CI, 21.34 to 2.33) and 1.09 (95% CI, 21.02 to 3.21), respectively, for those who were obese and nonadherent to their prescribed step 3 therapies. Survival curves for treatment and obesity status subgroups are shown in Fig 5. Our findings remained consistent after performing all sensitivity analyses.
DISCUSSION
In this real-life cohort of children with asthma, obese children experienced a higher risk of exacerbation when compared with nonobese children after initiation of ICS monotherapy or combination therapy. Our results also suggest that ICS monotherapy may be less effective in obese than nonobese children, whereas combination therapy appears to be equally effective across all weight classes. However, this differential response to step 3 maintenance therapies as a potential reason for this shorter exacerbation-free period in children with the obese-asthma phenotype cannot be ruled out, potentially because of a lack of precision.
Obesity was found to be a relevant determinant of exacerbation-free time for initiators of step 3 maintenance therapies in both the conditional and marginal models, although the latter model generated a stronger effect. This divergence can be explained by the fact that the conditional and marginal models estimate HRs under 2 distinct survival scenarios. The former compares the probability of an exacerbation between obese and nonobese children at observed event times T, given the child's covariate history and having not had an exacerbation until time T. Thus, children remaining under observation after time t are necessarily those who have not had an exacerbation at time T. This progressive ''selection'' of patients remaining under observation across follow-up who have not yet had an exacerbation leads to an inherent survival bias, 48, 52, 53 resulting in an underestimation of the true HR because the ''susceptibles'' have been removed from the population at risk. In contrast, the marginal model applies a weighting approach that emulates what would have happened to patients who were removed from the sample because of an early exacerbation had they, contrary to fact, remained under observation after the event. This allows for estimation of a marginal HR that avoids selection bias introduced by depletion of "susceptibles."
The increased exacerbation risk associated with obesity is consistent with 2 large studies, including a meta-analysis of 46,070 children by Ahmadizar et al 54 and a cohort of 32,231 children by Quinto et al, 24 demonstrating that obese children were 17% and 28% more likely to experience an exacerbation than their lean counterparts, respectively.
However, our findings differ from 2 other observational studies in the literature that reported null effects. Most recently, Lang et al 31 showed that obese children with asthma were not at greater risk for exacerbations than their normal-weight counterparts. Similarly, Kwong et al 33 observed no significant difference in the time required to achieve control for obese compared with nonobese children with asthma. These discordant findings might be due to methodological differences. The former study included both new and prevalent users of different asthma maintenance therapy regimens and reported exacerbation risk. Our outcome was defined as the time to first exacerbation in children who were new users of step 3 maintenance therapies, and our models accounted for the time-varying nature of drug exposure during follow-up. Although the study by Kwong et al 33 evaluated the effect of weight status on time to control, children not attending the second follow-up visit at the clinic were excluded; thus the inclusion of only those who had returned for the second follow-up visit might have led to an inherent bias and a significantly attenuated effect, ignoring the potential for early exacerbations. Our cohort study is the first to show that obese children might be susceptible to a shorter exacerbation-free period than nonobese children initiating step 3 maintenance therapies.
Although the obese-asthma phenotype has been characterized by noneosinophilic airway inflammation in some studies, [19] [20] [21] 55 ICS-based therapies shown to be effective in eosinophilic phenotypes might not be as effective in obese children. 30, 56 Our study findings suggest that obesity may be an important determinant of early exacerbations and provide an indication that ICS monotherapy may be less effective in obese than nonobese children, whereas similar beneficial effects were observed for combination therapy. Although no previous studies evaluated the differential response to step 3 maintenance therapies by obesity status in children, post hoc analyses in adults showed that obese asthmatic patients were less likely to respond to both ICS monotherapy and ICS/LABA combination therapy; however, this differential clinical response did not translate into *No use refers to periods of nonadherence to both step 3 maintenance therapies.
FIG 2.
Marginal probability of remaining exacerbation-free for obesity after initiation of step 3 maintenance therapy. The MSM estimates the marginal probability of remaining exacerbation-free had all patients been, contrary to fact, obese (red line) or nonobese (blue line) throughout follow-up. Survival curves were generated from the obesity MSM rather than the raw empiric data, which might have been misspecified.
FIG 3.
Marginal probability of remaining exacerbation-free after initiation of step 3 asthma maintenance therapy regimens by treatment status. The MSM estimates the marginal probability of remaining exacerbation-free had all patients been, contrary to fact, fully adherent to ICS monotherapy (red line), fully adherent to combination therapy (blue line), or completely nonadherent (gray line) throughout follow-up. Survival curves were generated from the treatment MSM rather than the raw empiric data, which might have been misspecified.
J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 4 an increased risk of exacerbation. 57, 58 The apparent divergence in findings with our real-life pediatric study could be due to different age groups, shorter follow-up, population homogeneity, and controlled conditions. Nonetheless, a suboptimal response to ICS monotherapy when compared with combination therapy may lead to treatment discontinuation because of perceived ineffectiveness and/or subsequent worsening of symptoms, resulting in a shorter exacerbation-free interval. The notion of ICS resistance in the obese-asthma phenotype has been highlighted in adults by Sutherland et al and others.
12,28,59 However, we could not rule out this hypothesis with our joint effect models because of a lack of precision in our estimates. The strengths of this study include specialist-confirmed asthma diagnosis, physician's global assessment of severity, standardized measurement of height and weight, and clinical information on key determinants of asthma control, minimizing confounding and misclassification of exposure. Linkage to the prescription claims database enabled assessment of varying drug use patterns during follow-up, which is a novel and important addition to the literature. This study has several limitations. First, patients eligible for cohort entry must have been covered by Quebec's public drug insurance program, leading to an underrepresentation of children from higher-income families. 60 The exclusion of children covered by private drug insurance plans resulted in a lack of precision, with wide CIs affecting our ability to rule out a potential differential treatment response by obesity status.
Second, patients followed in tertiary care asthma clinics are likely to have more severe symptoms than those in community settings; however, they are also more likely to achieve better control because they benefit from specialized care. 61 The selection of lower-income children with inadequately controlled asthma might have led to an underestimation of the true HR for obesity on time to exacerbation. Consequently, our findings might not be generalizable to the population of children with asthma covered by private drug insurance or those not benefitting from regular follow-up with their treating physicians.
Third, our method of defining periods of no use and exposure to step 3 therapies was dependent on the assumption that children used their treatments as prescribed. Violations of this assumption might have led to nondifferential misclassification of exposure, leading to underestimation of treatment effects.
Fourth, most children who were incident users of ICS monotherapy had not been previously prescribed a step 2 therapy, whereas this was much less common for combination therapy initiators. We suspect that physicians frequently initiated ICS monotherapy at a medium or high rather than a low dose because of the severity and poor control at the index visit or might have started combination therapy after a recent period of nonadherence to prior therapy.
Fifth, complications associated with obesity could be different by age group and stage of pubertal development; however, there was insufficient sample size to reliably explore whether results differed by age group.
Lastly, observational studies allow for possible confounding by indication; however, the high-quality clinical data obtained on asthma severity with a similar distribution of obese patients between step 3 maintenance therapies minimizes this possibility.
Our findings have important implications for clinical practice. Obese children with asthma appear to be more susceptible to early exacerbations after initiation of step 3 maintenance therapies; a different management approach may be warranted for obese children, pending improved weight status. Although there is no conclusive evidence with respect to the most effective step 3 strategy for this exacerbation-prone phenotype, our findings suggest that combination therapy with LABAs or LTRAs can confer a greater benefit than ICS monotherapy for children with the obese-asthma phenotype. Investigating the complex interplay between physiologic, environmental, and system-wide biomarkers underlying obese-asthma should be a research priority to inform management and treatment response prediction for this vulnerable patient group. Until new management FIG 5 . Marginal probability of remaining exacerbation-free for treatment groups by obesity status. The MSM estimates the probability of remaining exacerbation-free had all patients been, contrary to fact, obese and fully nonadherent (no use) to both step 3 maintenance therapies (black), nonobese and fully nonadherent (no use) to both step 3 maintenance therapies (gray), obese and fully adherent to ICS monotherapy (bright red), nonobese and fully adherent to ICS monotherapy (dark red), obese and fully adherent to combination therapy (bright blue), and nonobese and fully adherent to combination therapy (dark blue). Survival curves were generated from the obesity-by-treatment joint MSM, rather than the raw empiric data, which might have been misspecified. approaches are developed, careful monitoring of obese children initiating step 3 maintenance therapies might be reasonable. Given that obese children are frequently excluded from the drug development process, comparative efficacy and effectiveness studies with sufficient precision to further examine differential treatment response by weight status are needed.
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Clinical implications: Accumulating evidence suggests that current asthma management guidelines might be suboptimal for obese children with asthma. Alternative step 3 management preferences favoring combination therapy over higher-dose ICS monotherapy might be warranted for children with the obese-asthma phenotype.
METHODS
Conditional versus marginal structural Cox models
In the context of survival, analysis exposures and covariates can vary over time. The commonly used Cox proportional hazards model does not allow for proper handling of such time dependencies. However, extensions of the Cox model exist, such as the Andersen-Gill model, which allow for incorporation of time-varying covariates.
E1
In general, hazard regression models estimate conditional HRs, which compare the probability of an event between exposed and unexposed subjects at observed event time T given the patient's covariate history and having ''survived'' the event of interest until time T. Thus patients remaining under observation after time t are necessarily those who have not had the event at time T. This progressive ''selection'' of surviving or nonsusceptible patients across follow-up time leads to an inherent ''survival'' or ''depletion of susceptibles'' bias within the HR, the details of which have been well described by Hernan, Moride, and others in the literature. E2 This survival bias leads to an underestimation of the true HR and a spurious time-varying effect, in which harmful exposures can seem protective later during follow-up when the ''susceptibles'' have been removed from the population at risk.
More recently, MSMs have become used increasingly in the literature to estimate causal effects, which aim to overcome some of the shortcomings arising from conditional models. MSMs are grounded in a counterfactual framework, allowing one to answer a causal research question through the definition of specific counterfactual contrasts from the study's outset. MSMs use treatment weights to simulate what would have happened to patients who received a treatment or exposure had they, contrary to fact, not received this same treatment or exposure with respect to the outcome of interest. The treatment weights, referred to as inverse probability of treatment weights (IPTW), are computed by taking the inverse probability of receiving treatment for the treated (exposed) and the inverse probability of not receiving treatment for the untreated (unexposed). The propensity of receiving treatment is typically computed by using a logistic regression model that includes all potential confounders of the exposure-outcome relationship. This IPTW approach eliminates the need to condition on confounders because the weights create 2 completely exchangeable "pseudopopulations" (ie, counterfactual populations), which are devoid of confounding if all relevant confounders were included and correctly specified in the IPTW model (see Robins et al E3 for an overview of MSMs).
Furthermore, MSMs can be extended for time-to-event analyses, in which an additional weight for censoring can be used to simulate what would have happened to the patients lost to follow-up had they, contrary to fact, remained under observation. The censoring weights, referred to as IPCW, are computed by taking the inverse probability of remaining uncensored values and are updated for each follow-up time point. The propensity of remaining uncensored is, similarly to IPTW, estimated by using a logistic model for every time point that includes all potential common predictors for censoring and survival time. In practice, the IPCW approach emulates matching of subjects who are uncensored to those who are censored with similar characteristics at a specific time point. The uncensored, who closely resemble their censored counterparts, are then upweighted based on the inverse probability of remaining uncensored until this time point. Thus the IPCW approach eliminates the selection of only those remaining under observation through follow-up because the weights rebalance the sample by creating a pseudopopulation that is devoid of censoring. IPCW have been widely used to correct for the selection bias induced by informative censoring, such as artificial censoring for noncompliance and competing risks.
E4
To combine the advantages of IPTW and IPCW, new weights are computed by taking their product. Using these new weights in a weighted Cox regression model eliminates the need to condition on censoring or confounders. This weighted model is also known as the marginal structural Cox model.
In the article we have applied the IPCW approach to correct for survival bias inherent to the HR through weighting the MSM by the inverse probability of remaining event-free rather than the inverse probability of remaining uncensored. Using this weighting approach simulates what would have happened to patients who were removed from the sample because of an early observed event had they, contrary to fact, remained in the cohort after occurrence of the early event. This allows for estimation of a marginal HR that is not prone to selection bias introduced by depletion of susceptibles. We demonstrate the correction in Fig E1. 
Interpretation of conditional and marginal HRs
The conditional HR is the ratio of hazards for exposed to unexposed patients across follow-up given (''conditional on'') each patient's specific exposure and covariate history and survival up until the event of interest at time T. Accordingly, it is interpreted as the patient-level average effect. Importantly, this ''averaging'' occurs on the logarithmic scale of the HRs. The estimated conditional HR is then obtained by taking the antilog of the average of these log HRs across covariates. For example, if we were to condition on the covariate sex, the log HRs of exposed compared with unexposed must be computed for female and male subjects, respectively. To obtain the estimated conditional HR, we take the average of these sex-specific log HRs and apply the exponent (antilog) to this average. In the event that the distribution of female and male subjects is imbalanced in the sample, a weighted average is calculated.
In contrast, the marginal HR is the ratio of the average predicted hazards had all patients, contrary to fact, been exposed compared with unexposed throughout the entire length of follow-up. It is interpreted as the population-level average effect. Therefore the marginal approach uses averages of the hazards to determine the numerator and denominator of the HR, whereas the conditional approach uses the averages of the (log) HRs to estimate the overall covariate-adjusted HR.
The interpretation of the conditional HR can be complex. First, patients might have had different exposure and covariate trajectories over time, making inference to a target population challenging. For example, some patients might not use their medications as prescribed throughout follow-up, whereas others might be the opposite. The decision to adhere or not might depend on the evolution of lifestyle or disease characteristics throughout time for each patient, which could also affect future risk of having the event of interest. The difficulty interpreting the conditional HR occurs as a result of the risk sets constantly evolving throughout follow-up; one subject might be able to contribute exposed time in one follow-up interval and unexposed time in another depending on the risk set used for the calculation of the HR. If we imagine what this could mean in terms of the survival curves for the conditional HR, 1 subject might belong to the unexposed curve at one time point and then ''jump'' to the exposed curve at another time point. Moreover, the inherent survival bias associated with the conditional HR limits its clinical interpretation because inferences drawn from conventional hazard regression typically apply only to those patients who did not have previous events.
Marginal HRs are interpreted more easily from the public health and clinical perspectives. The advantage of the MSM is that it estimates an effect measure that eliminates ''jumping'' between exposed and unexposed survival curves at the patient level for different follow-up time points. At each time point, the MSM emulates what would have happened to patients who received treatment A had they, contrary to fact, received treatment B or been nonadherent to treatment A and vice versa. This allows for one to estimate the marginal average risk for those who would have been fully adherent to treatment A, fully adherent to treatment B, or fully nonadherent to both treatments throughout follow-up. The marginal HR is then computed by taking the ratios of the average marginal risks for each contrast (eg, risk of treatment A vs treatment B, treatment A vs nonadherent, and treatment B vs nonadherent), which is informed by the research question of interest. This is an added benefit to the clinical interpretation of the marginal HR.
Marginal structural model assumptions
The use of weighting approaches in MSMs, with IPTW, IPCW, or both, requires that certain assumptions are met: (1) IPTW, IPCW, or both models must be correctly specified (ie, all relevant confounding variables are included in the model or models and are appropriately represented so that they approximate the truly underlying nature of the relationship they build with the exposure and/or censoring mechanism) and (2) both the actual and estimated probabilities of being exposed to either exposure level have to be greater than zero for all subjects. If the actual probability of receiving a certain exposure is zero for some subjects, exposure groups might not be exchangeable with regard to their average baseline risks for the outcome. This is the case if factors that lead to exclusion of certain exposure scenarios are not independent of the outcome. Even if exchangeability is satisfied, estimated exposure or censorship probabilities based on small sample sizes or high-dimensional covariate settings might still take values close to zero. In such situations inverse probability weights become very large and can drastically inflate the variance of the estimated exposure effect, which is called practical violation of the positivity assumption. Weight stabilization can be used to reduce the severe effect of overly large weights on the effect estimate. E4 Validity of the consistency assumption is a third requirement to enable causal inference on treatment or exposure effects. It requires that exposures and outcomes are well defined and measured without substantial error. For example, nonadherence constitutes a major limiting factor in typical effectiveness studies because it violates the consistency assumption. In situations in which nonadherence can be assumed to be comparable across study groups, estimated magnitudes of exposure effects are typically biased toward a null effect. 
